

[Efavirenz + emtricitabine + tenofovir](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

Codes ATC: [J05AR06](#)

Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Code ICD11: [1C62.Z](#)

INN

Efavirenz + emtricitabine + tenofovir

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Historique des statuts LME

Ajouté pour la première fois en 2007 ([TRS 946](#))

Modifié en 2021 ([TRS 1035](#))

Sexe

Tous

Âge

Adolescents et adultes

Équivalence thérapeutique

[efavirenz + lamivudine + tenofovir](#) (Codes ATC: [J05AR11](#))

Renseignements sur le brevet

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Lire la suite [sur les brevets](#).

Wikipédia

[Efavirenz + emtricitabine + tenofovir](#)

DrugBank

[Efavirenz](#),

[Emtricitabine](#),

[Tenofovir disoproxil](#)

Résumé des preuves et recommandation du comité d'experts



Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.